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1. Introduction
Adoption of a new technology in surgery today is subject to
assessment by many stakeholders. These include surgeons,
patients, hospitals, regulators, and payers. The fundamental
tool for assessment is the determination of “value.” But value
has different meanings for each of the stakeholders.The usual
definition of value is “outcomedivided by cost.”Although cost
is usually measured in dollars, the measures for “outcome”
are not clearly defined nor agreed upon. What follows is
an attempt to define the value of robotic surgery in joint
replacement surgery for each of the stakeholders.
First, however, we need to understand that the primary
value of robotics in joint replacement is the reduction of
human error by improving accuracy and precision.This is the
same value that has resulted in adoption of robotics in most
manufacturing processes. A major part of quality control
in manufacturing is optimizing accuracy and precision by
reducing human error. Surgery, however, is a blend of intel-
ligence, art, and skill. There are many human skills that are
poorly performed by robots and vice versa. The appropriate
use of robotics in joint replacement surgery is intended to
improve the accuracy and precision of implant selection and
placement as well as execution by bone preparation.The goal
is not to replace the surgeon but to enhance the surgeon’s
performance. Robotics offers a tool that enables the surgeon
to reproduce his/her best performance on a consistent basis.
2. The Surgeon
Surgeons assess the value of new technology in terms of the
outcome of their patients as well as the effect on their practice.
The academic assessment of patient outcome has seen a
shift over the last 10+ years from surgeon-assessed measures
(like the Harris Hip Score or original Knee Society Score)
to patient-assessed measures (like the WOMAC or SF-36).
Recently, it has been recognized that more sensitive measures
like visual analog pain scales and patient satisfaction surveys
are needed to assess differences in higher levels of function.
Although surgeons follow the publications of these academic
outcome studies, the practical assessment of patient outcome
by the surgeon is a much more subjective process that is both
surgeon specific and practice specific.
Surgeons are concerned with performance. In this way
they are like professional athletes. Golfers prepare by using
“positive swing thoughts,” and quarterbacks focus on execu-
tion of a pass play not the last time they threw an intercep-
tion. Similarly, surgeons focus on how to achieve the best
performance for each surgery they attempt. As they mentally
prepare for their performance, they necessarily focus on
their past successful surgeries. And, just like the athletes,
they tend not to focus on their prior mistakes or failures.
This is necessary and effective prior to and during the
performance of a surgery. After the surgery, however, the best
surgeons and athletes analyze their performance critically.
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They acknowledge their mistakes and determine ways to
prevent them in the future. But most surgeons, like most
athletes, tend to gloss over theirmistakes and remember their
successes. This makes it difficult for them to determine the
value of a technology like robotics that is designed to reduce
human error.
The economic impact of adopting robotics on the sur-
geon’s practice has potentially both a positive and a negative
effect. By using a technology that improves the accuracy and
precision of their surgeries, they may attract more patients.
Some surgeries, however, at present require longer operating
times (10–20min).This can have a negative economic effect if
the surgeon is doing many joint replacements in a single day.
But, for most surgeons doing only a few joint replacements
in one day, the extra time would not allow the addition of
another case.There is also additional time required for preop
planning for robotic surgery (10–15min). But, again, for the
usual surgeon doing only a few cases each week, this addi-
tional time may not be significant.
3. The Patient
Cost is usually not an issue for the patient when determining
value, since most are covered by insurance and usually no
additional charges are passed on to the patient. Patients, how-
ever, obviously want the best outcome. Outcome can mean
different things to each patient. Indeed, a large part of obtain-
ing an informed consent from a patient is explaining to them
what to expect in terms of pain, function, and limitations as
well as reviewing the usual risks.What about the risk of using
robotics?
There is an inherent fear of robots on the part of patients.
In part, this is due to Hollywoodmovies and their fascination
with robots that go crazy and cause havoc. But patients are
also concerned that robots, like computers, may have “bugs”
in the programming or “crash” like their home computers.
Will the robot go crazy? This is where it is helpful to explain
to the patient how the development of robots in industry over
the last 30+ years has virtually eliminated robot error by the
use of redundancy and internal safety checks. The engineers
designing robots take Isaac Asimov’s First Law of Robotics
seriously: a robot is not allowed to harm a human. Only
human error can result in robot error. In this case, the human
is the surgeon. In robotic surgeries, the surgeon has some very
important responsibilities: select the best size and type of
implant for the patient, position it appropriately, and provide
the robot with a workspace such that no soft tissues are
damaged.
It is quite a big step for a patient to surrender his or her
body to a surgeon for an invasive procedure. It is also a very
subjective and emotional decision for the patient. Once they
have decided to have the surgery, they want to have faith
in their surgeon. They want to believe that their surgeon is
the best. Again, this presents a problem when telling patients
about using a technology that reduces human error. They
really do not like to think about their surgeon making errors.
Here, another reference to sports may help. If you ask the
patient who the best golfer in the world is, and then ask if
he always hits the ball in the middle of the fairway, they will
realize that even the best human skills are subject to error.
In this way, they will be much more receptive to the use of
robotic technology.
4. The Hospital
In my experience, hospitals are only concerned about patient
outcome in so far as it might relate to complications that arise
within the first 90 days. For hip replacement, robotics can
help in reducing early dislocations as well as intraoperative
fractures, but otherwise the use of this technology offers little
to reduce short-term complications.
Hospitals are most interested in cost and return on
investment “ROI.” Robotic systems can cost the hospitalmore
than $1 million. There are some small potential savings for
the hospital in terms of reduction of inventory and less use of
conventional instruments, but these “soft costs” are difficult
to measure. The true beneficiaries of reductions in inventory
and instruments are the implantmanufacturers. In the future,
the hospital may be able to negotiate a lower price for
implants used in robotic surgeries.
The cost of the technology to the hospital is mainly
offset, however, by attracting new patients and “filling beds,”
preferably with non-Medicare and noncapitated patients.
There is also the so-called “halo effect” where new technology
can attract patients that have other health problems which
can result in increased admissions and testing for other con-
ditions. If a preop CT scan is done (which is required by some
robotic systems for preoperative planning and mapping),
this may either be an additional source of revenue or expense
for the hospital depending on contracts with payors.
5. Regulators
The US FDA defines value in terms of safety and efficacy.
These requirements were stipulated in the 1974 Medical
Device Act which basically said that medical devices should
be treated in the same way as pharmaceuticals. They estab-
lished two different pathways to FDA clearance: the so-
called 510K pathway and the “Premarket Approval” pathway.
The 510K process is for devices that can be shown to be
“substantially equivalent” to a device already approved by the
FDA. The Premarket Approval process is for a new device
with no substantial equivalence to a device already on the
market.Most neworthopaedic devices are cleared by the 510K
process, since the Premarket Approval process is very costly
and usually takesmany years. For robotic devicemanufactur-
ers, the issue of showing substantial equivalence to an existing
device has been problematic. In the past, the 510K process
did not require new clinical data, whereas the Premarket
Approval process requires randomized controlled clinical tri-
als. Recently, however, there has been a trend to require clini-
cal data for many 510K applications. This may be in response
to significant problems with some 510K devices after they
have been cleared and in general use (e.g., metal-on-metal
hips).
Beginning in the late 1990s, a third requirement (in addi-
tion to showing safety and efficacy) has been added for clear-
ance called “clinical utility.” This is not defined by the FDA.
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In fact, they usually ask the applicant to define the clinical
utility of the device. Usually this has something to do with
cost-effectiveness. The criteria for meeting the clinical utility
standard are not clearly understood.
When it comes to evaluating the safety, efficacy, and
clinical utility of robotics, there has been some confusion. Is a
robot just a newmore sophisticated tool to be used in surgery,
like a smart reamer or saw? Are clinical data necessary? If
so, how long should the patients be followed after surgery?
If a complication arises, is it the tool that causes it, or is it
the inappropriate use of that tool by the surgeon? Is there
any real difference in control between semiactive (haptic)
robots where the surgeon guides the tool but the limits of
movement are restricted by the robot and active robots where
the cut paths of the tool are guided by the robot with the
same intended limits? These are all the questions under
consideration by the FDA.
6. Payers
Usually insurance companies do little new technology assess-
ment. If Medicare decides to cover something, they will
usually follow suit. So far, there is no CPT code for the use
of robotic surgery in joint replacement. Computer navigation
does have a code, but reimbursement by Medicare has been
spotty.
Payers should be most interested in reducing compli-
cations and improving longevity of the joint replacement.
Readmissions and revisions of failed implants are very costly.
Robotic joint replacement surgery offers the distinct possi-
bility to reduce human error in surgery. Data supporting the
reduction of complications or increased longevity of implants
put in with robotics have been difficult to obtain. Without
some data, some payers are unlikely to pay more for the use
of this technology.
7. Our Opinion
The intrinsic value of using robotics to improve accuracy and
precision in joint surgery will ultimately be recognized as
adding significant value. We expect to see a surge of interest
from surgeons in the future as new generations of robots with
robust applications will address many, if not all, of the out-
standing issues including ROI, reliability, better outcome, and
operative times.With increasing emphasis on outpatient par-
tial knee replacements, the role of robotic surgery in ambula-
tory surgery centers is a growing consideration and becoming
a greater reality, particularly as pricing of systems improves.
Current clinical applications of robotics in joint replacement
will improve and different applications to other aspects of
joint reconstructive surgery will be added.
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